The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
- Funded by National Institutes of Health (NIH)
- Total publications:1 publications
Grant number: 3U2CCA233238-01S1
Grant search
Key facts
Disease
COVID-19Start & end year
20182023Known Financial Commitments (USD)
$159,890Funder
National Institutes of Health (NIH)Principal Investigator
Avrum E SpiraResearch Location
United States of AmericaLead Research Institution
Boston University Medical CampusResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
In this proposal, that enhances ongoing Lung PCA studies, we propose aims to examine the protein localization, cell type specific expression, and biological pathways up-regulated with key SARS-CoV-2 viral entry genes across the various stages of lung cancer development. We will compare these results with protein expression of key SARS-CoV-2 viral entry genes as well as immune, epithelial, and endothelial cell proteins in lung tissue from patients that died from COVID-19, and from lung tissue sampled pre- and post-COVID-19 disease. Spatially characterizing the epithelium and stromal microenvironment and expression of key SARS-CoV-2 entry genes during the development of lung cancer in the central airway and the alveoli may identify potential ways to improve clinical management of this high-risk patient population and improve COVID-19 outcomes
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC